Barrier to autoimmune disease may open door to HIV, study suggests

July 11, 2017

Researchers from the University of Colorado School of Medicine have discovered that a process that protects the body from autoimmune disease also prevents the immune system from generating antibodies that can neutralize the HIV-1 virus. The findings, which will be published July 11 in The Journal of Experimental Medicine, might be considered by scientists trying to develop a vaccine that can stimulate the production of these neutralizing antibodies.

Some patients infected with HIV-1, the virus that causes AIDS, develop "broadly neutralizing antibodies" (bnAbs) that can protect against a wide variety of HIV-1 strains by recognizing a protein on the surface of the virus called Env. But the patients only develop these antibodies after many years of infection. Researchers are keen to discover how such bnAbs can be induced quickly in response to vaccinations against HIV-1.

bnAbs have several unusual features, including the fact that some of them often also recognize some of the body's own proteins. HIV-1-infected individuals may therefore take a long time to develop these antibodies because their production is suppressed by some of the mechanisms that prevent the body from generating self-reactive antibodies that could target healthy tissues and cause autoimmune diseases such as systemic lupus erythematosus (SLE). Patients with SLE show lower rates of HIV-1 infection, possibly because they produce self-reactive antibodies that can also recognize and neutralize HIV-1. Indeed, researchers recently identified one SLE patient who, though infected with HIV-1, could control her infection without the aid of antiretroviral drugs because she produced large amounts of bnAbs.

The process by which healthy individuals prevent the production of self-reactive antibodies is called immunological tolerance. B cells carrying potentially self-reactive antibodies can be eliminated while they are still developing in the bone marrow. And any self-recognizing B cells that escape this fate and enter the circulation are generally suppressed by the immune system so that they cannot mature into plasma cells that can secrete large amounts of the self-reactive antibody.

In the current study, a team of researchers led by Raul M. Torres, Professor of Immunology and Microbiology at the University of Colorado School of Medicine, investigated whether breaking these immunological tolerance mechanisms to allow the production of self-reactive antibodies would also facilitate the production of antibodies capable of neutralizing HIV-1.

The researchers first tested mice with genetic defects that cause lupus-like symptoms and found that many of these mice produced antibodies that could neutralize HIV-1 after they were injected with alum, a chemical that promotes antibody secretion and is often used as an adjuvant in vaccinations.

Next, the researchers treated normal, healthy mice with a drug that impairs immunological tolerance and found that these animals started to produce antibodies somewhat capable of neutralizing HIV-1. The production of these antibodies was increased by alum injection and, if the mice were also injected with the HIV-1 protein Env, the mice produced potent bnAbs that were able to neutralize a range of HIV-1 strains.

In all cases, the production of HIV-1 neutralizing antibodies correlated with the levels of a self-reactive antibody that recognizes a chromosomal protein called Histone H2A. The researchers purified these anti-H2A antibodies and confirmed that they were able to neutralize HIV-1.

"We think this may reflect an example of molecular mimicry where HIV-1 Env has evolved to mimic an epitope on histone H2A as a mechanism of immune camouflage," says Torres.

Immunological tolerance eliminates or suppresses any B cells capable of producing antibodies that recognize histone H2A, thereby limiting the ability to produce bnAbs.

"But breaching peripheral immunological tolerance permits the production of cross-reactive antibodies able to neutralize HIV-1," says Torres. "As this study was performed in an animal model, it will of course be important to determine its relevance for HIV immunity in humans. Here, primary consideration will be determining whether immunological tolerance can be transiently relaxed without leading to detrimental autoimmune manifestations and as a means to possibly elicit HIV-1 bnAbs with vaccination."
-end-
Schroeder et al., 2017. J. Exp. Med.http://jem.rupress.org/cgi/doi/10.1084/jem.20161190?PR

About The Journal of Experimental Medicine

The Journal of Experimental Medicine (JEM) features peer-reviewed research on immunology, cancer biology, stem cell biology, microbial pathogenesis, vascular biology, and neurobiology. All editorial decisions are made by research-active scientists in conjunction with in-house scientific editors. JEM provides free online access to many article types from the date of publication and to all archival content. Established in 1896, JEM is published by The Rockefeller University Press. For more information, visit jem.org.

Visit our Newsroom, and sign up for a weekly preview of articles to be published. Embargoed media alerts are for journalists only.

Follow JEM on Twitter at @JExpMed and @RockUPress.

Rockefeller University Press

Related Immune System Articles from Brightsurf:

How the immune system remembers viruses
For a person to acquire immunity to a disease, T cells must develop into memory cells after contact with the pathogen.

How does the immune system develop in the first days of life?
Researchers highlight the anti-inflammatory response taking place after birth and designed to shield the newborn from infection.

Memory training for the immune system
The immune system will memorize the pathogen after an infection and can therefore react promptly after reinfection with the same pathogen.

Immune system may have another job -- combatting depression
An inflammatory autoimmune response within the central nervous system similar to one linked to neurodegenerative diseases such as multiple sclerosis (MS) has also been found in the spinal fluid of healthy people, according to a new Yale-led study comparing immune system cells in the spinal fluid of MS patients and healthy subjects.

COVID-19: Immune system derails
Contrary to what has been generally assumed so far, a severe course of COVID-19 does not solely result in a strong immune reaction - rather, the immune response is caught in a continuous loop of activation and inhibition.

Immune cell steroids help tumours suppress the immune system, offering new drug targets
Tumours found to evade the immune system by telling immune cells to produce immunosuppressive steroids.

Immune system -- Knocked off balance
Instead of protecting us, the immune system can sometimes go awry, as in the case of autoimmune diseases and allergies.

Too much salt weakens the immune system
A high-salt diet is not only bad for one's blood pressure, but also for the immune system.

Parkinson's and the immune system
Mutations in the Parkin gene are a common cause of hereditary forms of Parkinson's disease.

How an immune system regulator shifts the balance of immune cells
Researchers have provided new insight on the role of cyclic AMP (cAMP) in regulating the immune response.

Read More: Immune System News and Immune System Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.